Class summary at a glance.

Every drug in the Adenosine Triphosphate-Citrate Lyase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $118.1Mcombined across class
Total Rx claims: 163K58K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bempedoic Acid

Brand: Nexletol · 163K Part D claims (CY24) · 58K beneficiaries · First FDA approval: 2020-03-06

Brand-only (no generics) 160 plans require PA

Low NADAC$13.80

→

Avg plan cost$13.80

Part D spend $118.1M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Bempedoic Acid and Ezetimibe

Brand: Nexlizet · — Part D claims (CY24) · First FDA approval: 2020-03-09

Brand-only (no generics) 144 plans require PA

Low NADAC$13.84

→

Avg plan cost$13.84

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.